Indeed, the FFA2 antagonist 4-[[1-(benzo[b]thiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-(3-chlorobenzyl)amino]butyric acid (GLPG0974) entered phase II clinical trials for treatment of ulcerative colitis but failed to show efficacy13. This evidence concerns the gene FFAR2 and ulcerative colitis.